Vaxcyte, Inc.

What they do

Vaxcyte engineers conjugate and protein vaccine candidates for bacterial diseases, led by its pneumococcal conjugate vaccine (PCV) franchise (VAX-31, VAX-24, VAX-XL) and the early-stage VAX-A1 candidate for Group A Streptococcus. It uses the XpressCF cell-free protein synthesis platform to produce difficult-to-make proteins and antigens, and describes its PCV candidates as carrier-sparing and broad-spectrum. The company has no products approved for commercial sale and has devoted substantially all resources to research, preclinical studies, clinical trials and manufacturing enablement.

Revenue drivers

• PCV franchise - VAX-31 adult indication — Lead asset; a 31-valent investigational PCV in three fully enrolled Phase 3 adult trials (OPUS-1, OPUS-2, OPUS-3) with 6,191 adults dosed in total, approximately 3,500 of whom received VAX-31. No revenue today; targets the approximately $8 billion global pneumococcal vaccine market.
• PCV franchise - VAX-31 infant indication — Phase 2 dose-finding infant study fully enrolled, with topline data from the primary immunization series and booster dose expected either sequentially or together by end of first half of 2027.
• VAX-A1 — Prophylactic vaccine candidate designed to prevent disease caused by Group A Streptococcus; Phase 1 study in healthy adults initiated, with topline data expected in the second half of 2027.
• VAX-XL — Preclinical, next-generation PCV candidate designed to provide the broadest coverage of any PCV currently in development; no revenue and no clinical-stage timeline disclosed in the excerpts.

Recent performance

Vaxcyte reported a net loss of $766.6 million for 2025, or diluted EPS of -$5.63, versus a net loss of $463.9 million (-$3.80) in 2024. Operating cash flow was negative $655.6 million in 2025, compared with negative $452.6 million in 2024. As of June 30, 2026, the company reported total assets of $3.14 billion, total liabilities of $380.2 million, shareholder equity of $2.76 billion, and cash and equivalents of $183.2 million, while the August 5, 2026 earnings release cited approximately $2.5 billion in cash, cash equivalents and investments as of June 30, 2026. No dividends have been paid in any year from 2021 through 2025.

Strategy

The company is focused on executing late-stage development of VAX-31, with all three Phase 3 OPUS trials fully enrolled and a manufacturing consistency (lot-to-lot) study planned as the final Phase 3 study to enable a BLA submission. Management said the OPUS-2 and OPUS-3 results in the first half of 2027, together with the manufacturing consistency study, would enable the planned BLA submission and potential U.S. commercial launch. It is also advancing early-stage pipeline programs, including the Phase 1 VAX-A1 study and preclinical VAX-XL. Management stated it is preparing for the company's next phase of growth and commercial readiness.

Risks

• No approved products or commercial history — Vaxcyte has no products approved for commercial sale and has not demonstrated an ability to complete clinical development, obtain regulatory approvals, manufacture at commercial scale, or conduct sales and marketing.
• Clinical and regulatory failure risk — The pipeline depends on VAX-31 Phase 3 outcomes, including OPUS-1 topline data expected in the fourth quarter of 2026 and OPUS-2/OPUS-3 in the first half of 2027; negative results would delay or prevent BLA submission.
• Mounting cash burn — Net loss widened to $766.6 million in 2025 from $463.9 million in 2024, and operating cash flow was negative $655.6 million, requiring continued capital to fund late-stage trials and manufacturing.
• Competitive standard of care — OPUS-1 compares VAX-31 head-to-head with Prevnar 20 (PCV20) and Capvaxive (PCV21), and the company's case for VAX-31 depends on demonstrating a best-in-class profile against these marketed PCVs.

Outlook

Management expects topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial in the fourth quarter of 2026, with OPUS-2 and OPUS-3 results in the first half of 2027. It expects topline data from the VAX-31 infant Phase 2 dose-finding study, covering the primary immunization series and booster dose, either sequentially or together by the end of the first half of 2027. Topline data from the VAX-A1 Phase 1 study are expected in the second half of 2027. Management stated that OPUS-2, OPUS-3 and a manufacturing consistency study would enable the planned BLA submission and potential U.S. commercial launch.